放射線皮膚炎の市場規模、シェア、成長分析：製品別、流通チャネル別、地域別 - 産業予測 2025～2032年

放射線皮膚炎の世界市場規模は、2023年に4億5,236万米ドルと評価され、2024年の4億7,091万米ドルから2032年には6億4,944万米ドルに成長し、予測期間（2025年～2032年）のCAGRは4.1％で成長する見通しです。

放射線皮膚炎の市場は、乳がん患者の85～95％を含むがん患者の95％がさまざまな形態の放射線皮膚炎に罹患しており、放射線療法に関連した皮膚問題の影響が大きいため、需要が高まっています。COVID-19パンデミックは当初、パンデミック治療にリソースを振り向け、放射線治療のセッションを減らすことで市場の成長を阻害したが、規制の緩和により腫瘍学サービスの復活が促進されました。さらに、糖尿病と肥満の有病率の上昇により、がん患者の増加が予想され、2030年までに12億人の糖尿病患者が発生すると予測されています。このような患者、特に合併症を持つ患者の増加は、放射線による皮膚合併症を悪化させ、今後の放射線皮膚炎の市場に貴重な機会をもたらす可能性が高いです。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• 技術評価
• 特許分析
• パイプライン分析

放射線皮膚炎市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 話題
  • コルチコステロイド
  • 親水性クリーム
  • 抗生物質
  • その他
• 経口薬
• ドレッシング
  • ハイドロゲルおよびハイドロコロイドドレッシング
  • 刺傷防止フィルム
  • 蜂蜜を染み込ませたガーゼ
  • シリコンコーティングドレッシング
  • その他

放射線皮膚炎市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

放射線皮膚炎市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• 3M Company（United States）
• Smith & Nephew plc（United Kingdom）
• Investor AB（Molnlycke Health Care AB）（Sweden）
• BMG Pharma S.p.A.（Italy）
• Stratpharma Inc.（Switzerland）
• Bausch Health Companies Inc.（Canada）
• Bayer AG（Germany）
• Paul Hartmann AG（Germany）
• KeraNetics, Inc.（United States）
• Charles River Laboratories（United States）
• The Jackson Laboratory（United States）
• InterMed S.A.（Greece）
• AceTech（South Korea）
• KCI Licensing Inc.（Acelity）（United States）
• Derma Sciences Inc.（Integra LifeSciences）（United States）
• Ligand Pharmaceuticals Inc.（Apeiron Biologics）（United States）
• Lutris Pharma Ltd.（Israel）
• GlaxoSmithKline plc（United Kingdom）
• ConvaTec Group plc（United Kingdom）
• Viatris Inc（United States）

結論と推奨事項

Global Radiodermatitis Market size was valued at USD 452.36 million in 2023 and is poised to grow from USD 470.91 million in 2024 to USD 649.44 million by 2032, growing at a CAGR of 4.1% during the forecast period (2025-2032).

The radiodermatitis treatment market is witnessing heightened demand due to the significant impact of radiation therapy-related skin issues, with 95% of cancer patients, including 85-95% of breast cancer patients, affected by varying forms of radiodermatitis. Although the COVID-19 pandemic initially obstructed market growth by diverting resources to pandemic care and reducing radiation therapy sessions, the easing of restrictions has facilitated a resurgence in oncology services. Moreover, the rising prevalence of diabetes and obesity is expected to increase cancer cases, with projections estimating 1.2 billion diabetes cases by 2030. This growing patient population, particularly those with co-morbidities, will likely exacerbate radiation-induced skin complications and generate valuable opportunities in the radiodermatitis treatment market moving forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Radiodermatitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Radiodermatitis Market Segmental Analysis

Global Radiodermatitis Market is segmented by Product, Distribution Channel and region. Based on Product, the market is segmented into Topical, Oral Drugs and Dressings. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Radiodermatitis Market

One of the primary drivers of the global radiodermatitis market is the rising utilization of radiation therapy in cancer treatments. As more patients undergo radiation therapy as part of their oncology care, the prevalence of radiodermatitis, a common side effect associated with such treatments, is also on the rise. This surge in cases necessitates a corresponding increase in the availability and development of effective treatments and management options for radiodermatitis. Consequently, the expanding recognition of radiation therapy's role in cancer management directly fuels the growth of the radiodermatitis market, reflecting the urgent need for addressing the associated skin complications.

Restraints in the Global Radiodermatitis Market

The global radiodermatitis market faces significant restraints primarily due to the side effects and adverse reactions associated with various treatment options. These complications can restrict the applicability of certain therapies within specific patient populations, leading to hesitancy among healthcare providers and patients alike. Such concerns about safety and tolerability may inhibit the widespread adoption of some treatment modalities, consequently impacting the overall growth potential of the market. As a result, addressing these limitations is crucial for the advancement and acceptance of innovative therapies aimed at effectively managing radiodermatitis.

Market Trends of the Global Radiodermatitis Market

The Global Radiodermatitis market is experiencing a notable shift towards the adoption of advanced treatment options, reflecting a significant trend in patient care management. Innovative therapies, including advanced topical products and specialized dressings, are increasingly sought after for their efficacy in alleviating radiation-induced skin damage. As healthcare providers recognize the importance of enhancing patient quality of life during cancer treatments, the demand for these advanced solutions is projected to rise. This trend is further fueled by ongoing research and development, resulting in more targeted treatments that address the complexities of radiodermatitis, ultimately driving market growth and diversification.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Technology Assessment
• Patent Analysis
• Pipeline Analysis

Global Radiodermatitis Market Size by Product & CAGR (2025-2032)

• Market Overview
• Topical
  • Corticosteroids
  • Hydrophilic Creams
  • Antibiotics
  • Others
• Oral Drugs
• Dressings
  • Hydrogel & Hydrocolloid dressings
  • No Sting Barrier Film
  • Honey-impregnated Gauze
  • Silicone Coated Dressings
  • Others

Global Radiodermatitis Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Radiodermatitis Market Size & CAGR (2025-2032)

• North America (Product, Distribution Channel)
  • US
  • Canada
• Europe (Product, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• 3M Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith & Nephew plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Investor AB (Molnlycke Health Care AB) (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BMG Pharma S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stratpharma Inc. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Paul Hartmann AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KeraNetics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• The Jackson Laboratory (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InterMed S.A. (Greece)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AceTech (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KCI Licensing Inc. (Acelity) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Derma Sciences Inc. (Integra LifeSciences) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ligand Pharmaceuticals Inc. (Apeiron Biologics) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lutris Pharma Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ConvaTec Group plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations